MNKD
NASDAQMannKind Corporation
Website
News25/Ratings12
News · 26 weeks52-89%
2025-10-262026-04-19
Mix2990d
- Insider14(48%)
- Other8(28%)
- SEC Filings4(14%)
- Earnings2(7%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form DEFA14A filed by MannKind CorporationDEFA14A - MANNKIND CORP (0000899460) (Filer)
- SECSEC Form DEF 14A filed by MannKind CorporationDEF 14A - MANNKIND CORP (0000899460) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by MannKind CorporationSCHEDULE 13G/A - MANNKIND CORP (0000899460) (Subject)
- INSIDERSEC Form 4 filed by Prentiss Christopher B4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERSEC Form 4 filed by Castagna Michael4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERSEC Form 4 filed by Singh Sanjay R4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERSEC Form 4 filed by Thomson David4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERSEC Form 4 filed by Ahuja Ajay4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERSEC Form 4 filed by Tross Stuart A4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERChief Executive Officer Castagna Michael bought $259,000 worth of shares (100,000 units at $2.59), increasing direct ownership by 4% to 2,575,911 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- PRMannKind to Present New Data From Pediatric and Adult Studies of Afrezza® at ATTD 2026Presentations highlight real‑world dosing and titration patterns in youth, and post‑prandial glucose management strategies using inhaled insulin in both adults and youth with T1DData to be featured across oral and poster sessions at the Advanced Technologies & Treatments for Diabetes Conference (ATTD)PDUFA target action date for Afrezza in children and adolescents living with type 1 or type 2 diabetes set for May 29, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lu
- PRMannKind Announces Settlement of Convertible Senior NotesDANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced the settlement of the remaining $36.3 million aggregate principal amount of 2.50% convertible senior notes, all of which were tendered for conversion prior to the maturity date of March 1, 2026. The settlement was made on March 4, 2026, with $35.5 million in cash and 569,023 shares of MannKind common stock. About MannKindMannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize t
- PRMannKind to Participate in Upcoming Investor ConferencesDANBURY, Conn. and WESTLAKE VILLAGE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today its attendance at two upcoming investor conferences, at which MannKind's Chief Executive Officer, Michael Castagna, PharmD, and Chief Financial Officer, Chris Prentiss will participate in fireside chats and in 1x1 meetings with investors. Leerink Partners 2026 Global Healthcare Conference in MiamiTuesday, March 10, 3:40 p.m. ET Barclays 28th Annual Global Healthcare Conference in MiamiWednesday, March 11, 1:00 p.m. ET Links to the live audio webcast of the sessions will be available on MannKind Corporation's website at: https://investors.mannkindcorp.com/ev
- INSIDERDirector Hooper Anthony C was granted 35,000 shares, increasing direct ownership by 17% to 236,153 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERChief Financial Officer Prentiss Christopher B was granted 5,000 shares, increasing direct ownership by 1% to 348,854 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERDirector Shannon James Samuel was granted 12,000 shares, increasing direct ownership by 23% to 64,635 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERSEC Form 4 filed by Director Binder Steven B.4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERSEC Form 4 filed by EVP Genl Counsel & Secretary Thomson David4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERChief Executive Officer Castagna Michael was granted 15,290 shares, increasing direct ownership by 0.62% to 2,475,911 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- INSIDERChief People & Workpl Officer Tross Stuart A was granted 15,290 shares, increasing direct ownership by 2% to 1,000,297 units (SEC Form 4)4 - MANNKIND CORP (0000899460) (Issuer)
- ANALYSTMannkind downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded Mannkind from Outperform to Sector Perform and set a new price target of $3.50
- SECSEC Form 10-K filed by MannKind Corporation10-K - MANNKIND CORP (0000899460) (Filer)
- SECMannKind Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - MANNKIND CORP (0000899460) (Filer)
- PRMannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateQ4 2025 revenues of $112M, +46% vs. Q4 2024 Furoscix® Q4 2025 net sales of $23M, +91% vs. Q4 2024 Afrezza® Q4 2025 net sales of $23M, +25% vs. Q4 2024 2025 full year revenues of $349M, +22% vs. 2024Successfully completed the acquisition of scPharmaceuticals Inc. (scPharma)Program updates: Afrezza pediatric indication PDUFA date May 29, 2026Furoscix ReadyFlow™ Autoinjector PDUFA date July 26, 2026 DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today reporte
- PRMannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences ConferenceDANBURY, Conn. and WESTLAKE VILLAGE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), today announced Chief Executive Officer Michael Castagna, PharmD is scheduled to present and share business updates during the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026, at 11:20 a.m. ET A link to the webcast of the presentation will be available on MannKind Corporation's website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference. About MannKind MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical compa